TSAAI 2021 Annual Meeting
It is an exciting time in the field of allergy and immunology! This CME program is designed to allow attendees to continue exploring the Immunology Frontier. Covered topics include current and emerging treatments in HAE, Peanut Immunotherapy, translational targets for new asthma therapeutics, and updates on immunodeficiencies.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Tennessee Society of Allergy, Asthma and Immunology. The American College of Allergy, Asthma, and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians..
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
This activity is supported in part by a medical education grant from CSL Behring.
Allied health professionals
Upon completion of this activity the participant should be able to:
- Recognize the mechanism of action o the different biologics available to treat severe asthma
- Describe when and how to initiate appropriate treatment with specific biologics
All identified conflicts of interest have been mitigated.
The individuals listed below disclose the following financial relationships:
- 7.00 AMA PRA Category 1 Credit™
- 7.00 Attendance